TY  - JOUR
A1  - Foocharoen, Chingching
A1  - Tyndall, Alan
A1  - Hachulla, Eric
A1  - Rosato, Edoardo
A1  - Allanore, Yannick
A1  - Farge-Bancel, Dominique
A1  - Caramaschi, Paola
A1  - Airó, Paolo
A1  - Nikolaevna, Starovojtova M.
A1  - Pereira da Silva, José A.
A1  - Stamenkovic, Bojana
A1  - Riemekasten, Gabriela
A1  - Rednic, Simona
A1  - Sibilia, Jean
A1  - Wiland, Piotr
A1  - Tarner, Ingo
A1  - Smith, Vanessa
A1  - Onken, Anna Theresa
A1  - Abdel Atty Mohamed, Walid A.
A1  - Distler, Oliver
A1  - Morović-Vergles, Jadranka
A1  - Himsel, Andrea
A1  - de la Peña Lefebvre, Paloma G.
A1  - Hügle, Thomas
A1  - Walker, Ulrich A.
T1  - Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group
T2  - Arthritis research & therapy
N2  - Introduction: Erectile dysfunction (ED) is common in men with systemic sclerosis (SSc) but the demographics, risk factors and treatment coverage for ED are not well known.

Method: This study was carried out prospectively in the multinational EULAR Scleroderma Trial and Research database by amending the electronic data-entry system with the International Index of Erectile Function-5 and items related to ED risk factors and treatment. Centres participating in this EULAR Scleroderma Trial and Research substudy were asked to recruit patients consecutively.

Results: Of the 130 men studied, only 23 (17.7%) had a normal International Index of Erectile Function-5 score. Thirty-eight per cent of all participants had severe ED (International Index of Erectile Function-5 score ≤ 7). Men with ED were significantly older than subjects without ED (54.8 years vs. 43.3 years, P < 0.001) and more frequently had simultaneous non-SSc-related risk factors such as alcohol consumption. In 82% of SSc patients, the onset of ED was after the manifestation of the first non-Raynaud's symptom (median delay 4.1 years). ED was associated with severe cutaneous, muscular or renal involvement of SSc, elevated pulmonary pressures and restrictive lung disease. ED was treated in only 27.8% of men. The most common treatment was sildenafil, whose efficacy is not established in ED of SSc patients.

Conclusions: Severe ED is a common and early problem in men with SSc. Physicians should address modifiable risk factors actively. More research into the pathophysiology, longitudinal development, treatment and psychosocial impact of ED is needed.
Y1  - 2012
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/24403
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-244039
SN  - 1478-6354
SN  - 1478-6362
SN  - 1465-9913
VL  - 14
IS  - issue 1 art 14:R37
SP  - 1
EP  - 10
PB  - BioMed Central
CY  - London
ER  -